Eyenovia, Inc. (NASDAQ:EYEN) CEO Acquires $28,500.00 in Stock

Eyenovia, Inc. (NASDAQ:EYEN) CEO Michael M. Rowe acquired 50,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were acquired at an average cost of $0.57 per share, for a total transaction of $28,500.00. Following the transaction, the chief executive officer now owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Eyenovia Stock Performance

EYEN traded up $0.03 on Tuesday, hitting $0.56. 1,975,025 shares of the stock traded hands, compared to its average volume of 1,252,939. The business has a fifty day moving average price of $0.91 and a two-hundred day moving average price of $1.02. The company has a current ratio of 0.88, a quick ratio of 0.66 and a debt-to-equity ratio of 3.72. Eyenovia, Inc. has a 52 week low of $0.37 and a 52 week high of $2.57. The firm has a market capitalization of $29.96 million, a PE ratio of -0.71 and a beta of 1.77.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Eyenovia in a research note on Tuesday, August 13th.

Hedge Funds Weigh In On Eyenovia

Hedge funds and other institutional investors have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. bought a new position in Eyenovia during the second quarter worth about $26,000. Ground Swell Capital LLC acquired a new position in Eyenovia in the second quarter valued at about $27,000. Nations Financial Group Inc. IA ADV grew its stake in Eyenovia by 24.4% during the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after buying an additional 10,000 shares during the last quarter. Leo Wealth LLC acquired a new stake in shares of Eyenovia during the fourth quarter worth approximately $34,000. Finally, PFG Investments LLC acquired a new position in shares of Eyenovia in the 1st quarter worth approximately $69,000. 25.84% of the stock is owned by institutional investors.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.